[go: up one dir, main page]

AU2002333079A1 - Individualization of therapy with anxiolitics - Google Patents

Individualization of therapy with anxiolitics

Info

Publication number
AU2002333079A1
AU2002333079A1 AU2002333079A AU2002333079A AU2002333079A1 AU 2002333079 A1 AU2002333079 A1 AU 2002333079A1 AU 2002333079 A AU2002333079 A AU 2002333079A AU 2002333079 A AU2002333079 A AU 2002333079A AU 2002333079 A1 AU2002333079 A1 AU 2002333079A1
Authority
AU
Australia
Prior art keywords
anxiolitics
individualization
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002333079A
Inventor
Brian Leyland-Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/072,611 external-priority patent/US20030091975A1/en
Priority claimed from US10/100,272 external-priority patent/US20030175210A1/en
Application filed by McGill University filed Critical McGill University
Publication of AU2002333079A1 publication Critical patent/AU2002333079A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948Sedatives, e.g. cannabinoids, barbiturates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Pathology (AREA)
  • Anesthesiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Composite Materials (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2002333079A 2002-02-08 2002-10-08 Individualization of therapy with anxiolitics Abandoned AU2002333079A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/072,611 US20030091975A1 (en) 2001-02-09 2002-02-08 Multiple determinants for metabolic phenotypes
US10/072,611 2002-02-08
US10/100,272 US20030175210A1 (en) 2001-03-14 2002-03-14 Individualization of therapy with anxiolitics
US10/100,272 2002-03-14
PCT/CA2002/001512 WO2003067257A1 (en) 2002-02-08 2002-10-08 Individualization of therapy with anxiolitics

Publications (1)

Publication Number Publication Date
AU2002333079A1 true AU2002333079A1 (en) 2003-09-02

Family

ID=27736814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002333079A Abandoned AU2002333079A1 (en) 2002-02-08 2002-10-08 Individualization of therapy with anxiolitics

Country Status (2)

Country Link
AU (1) AU2002333079A1 (en)
WO (1) WO2003067257A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2167330A1 (en) * 1996-01-31 1997-08-01 Xanthus Life Sciences, Inc. Elisa kit for the rapid determination of n-acetyltransferase (nat2) phenotypes
AU3138800A (en) * 1999-03-15 2000-10-04 Brian Leyland-Jones Elisa kit for the determination of metabolic phenotypes

Also Published As

Publication number Publication date
WO2003067257A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
AU2003224725A1 (en) Hiv therapeutic
AU2003280262A1 (en) Individualization of therapy with anticoagulants
AU2002244568A1 (en) Individualization of therapy with antipsychotics
AU2003247005A1 (en) Therapy combination
AU2003249722A1 (en) Therapeutic amides
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2003215150A1 (en) Therapeutic compounds
AU2002302223A1 (en) Individualization of therapy with analgesics
AU2002335667A1 (en) Modified reoviral therapy
AU2003219580A1 (en) Novel therapeutical use of byakangelicin
AU2002244575A1 (en) Individualization of therapy with antidepressants
AU2002349225A1 (en) Individualization of therapy with antiviral agents
AU2003900495A0 (en) Aroylhydrazone derivatives and therapeutic uses thereof
AU2003285079A1 (en) Neurostimulation therapy manipulation
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2002953223A0 (en) Novel therapeutic molecules and uses thereof
AU2003240052A1 (en) Il-11 derivatives and therapeutic uses thereof
AU2002257411A1 (en) Individualization of therapy with antineoplastic agents
AU2002350344A1 (en) Individualization of therapy with antihistamines
AU2002257451A1 (en) Individualization of therapy with antibiotic agents
AU2002333079A1 (en) Individualization of therapy with anxiolitics
AU2003231937A1 (en) Therapeutic methods
AU2002342488A1 (en) Individualization of therapy with anesthetics
AU2002953516A0 (en) Genetic therapy and genetic modification
AU2003287840A1 (en) Arylthioetherpyrimidine and aryloxyetherpyrimidine derivatives and their therapeutic uses

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase